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ICS expenditures and use (2003–2004) among Medicare+Choice
beneﬁciaries with asthma, and a high-severity asthma subgroup.
METHODS: We used automated data from an integrated deliv-
ery system in the U.S. All subjects were continuously enrolled,
age 65+, asthma-registry members with prior ICS use, and had
$10 generic-copayments and no chronic obstructive pulmonary
disorder diagnoses or ipratropium bromide use (n = 2,908). In
2004, 74.0% switched from a $30 brand-copayment with a
$1000 annual cap, to generic-only coverage (full-price for brand-
drugs), with no cap; 26.0% had $15–25 brand-copayments
2003–2004 (control-group). We used linear difference-in-differ-
ence models to examine changes (2003–2004) in ICS expendi-
tures (total and out-of-pocket) and use (days-of-supply). Models
adjusted for gender, age, race/ethnicity, neighborhood socioeco-
nomic-status, comorbidity, chronic diseases, and asthma 
characteristics (high-risk asthma-ﬂag, high-dose ICS, prior
asthma-related emergency or hospital visits, oral steroid use, and
ICS type). We deﬁned patients as having high-severity asthma if
they had a high-risk ﬂag or a high-dose ICS prescription (n =
798). RESULTS: In multivariate analyses, patients who lost
brand-coverage had lower total ICS expenditures (−$106,
[95%CI: −$125 to −$87]), but higher out-of-pocket expenditures
($52, [$40 to $64]), compared with patients with no coverage
changes; ICS days-of-supply were also lower (−11.6 days, [−18.5
to −4.8]). Among high-severity asthma patients, loss of brand-
coverage was associated with changes similar in direction, but
larger in magnitude: total ICS expenditures (−$270, [−$322 to 
−$219]); out-of-pocket expenditures ($74, [$43 to $104]); and
days-of-supply (−24.2, [−37.6 to −10.9]). CONCLUSIONS:
Patients with generic-only coverage had higher out-of-pocket
costs and lower total expenditures and days-of-supply for
inhaled corticosteroids. These changes were greater among high-
severity asthma patients. Future research will examine the clini-
cal effects of these changes.
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OBJECTIVES: The objective of this study is to evaluate the effect
of health plan structure on health care utilization and expendi-
tures for asthma care. Some health plans in the USA require a
designated primary care physician (PCP plans) and some do not
(NPCP plans). METHODS: Our data was drawn from the
MEDSTAT MarketScan database. The sample had 330,685
patients with either at least one hospitalization or at least two
outpatient visits for asthma during 1998–2001. Approximately
47% (154,106) of the patients had PCP plans; the remainder had
NPCP health plans. We performed regression analysis to
examine the effect of having a primary care physician and capi-
tation in the health plan on expenditures for asthma, controlling
for gender, age, employment status, and health status via the
Charlson comorbidity index. RESULTS: We found annual per
capita inpatient expenditures for asthma were about 8.4% lower
for the patients in the PCP plans compared to the patients in the
NPCP plans (p < 0.01), with a mean length of stay 0.07 days
shorter (p < 0.01) and 0.02 times fewer admissions (p < 0.01)
per year for asthma. However, annual per capita outpatient
expenditures for asthma were 9.1% higher in the PCP plans com-
pared to the NPCP plans (p < 0.01) as PCP asthma patients
received 1.4 more outpatient services per year (p < 0.01) and
about 0.2 more outpatient visits (p < 0.01) per year than NPCP
asthma patients. On net, total expenditures were 3.2% lower for
PCP asthma patients (p < 0.01) than for NPCP asthma patients.
CONCLUSIONS: For asthma care, there is a tradeoff between
relatively inexpensive outpatient services and more expensive
inpatient services. Results of this study suggest that patients with
asthma enrolled in PCP plans used signiﬁcantly more outpatient
services and fewer inpatient services, resulting in lower overall
spending.
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OBJECTIVE: The study is focused on the potential impacts of
genome-based technologies on health care. We have chosen
asthma in children as a case study and gene-screening as the tech-
nology assessed to explore the cost-effectiveness of applying an
early genetic- screening to newborns and a preventive treatment
to the population at risk. METHODS: A Markov model con-
sisting on six mutually exclusive disease states with a simulation
horizon of 100 years was constructed. Two different scenarios
were deﬁned. RESULTS: In the base case and for scenario 1, the
number of quality adjusted life years (QALY) gained is 4.081
and the incremental cost-effectiveness ratio per QALY gained is
€40416.1/QALY. In scenario 2, the number of QALYs gained is
1.483 and the incremental cost-effectiveness ratio per QALY
gained falls to €18474.27/QALY. We have carried out a sensi-
tivity analysis varying the discount rate, the cost of genetic
testing and considering two different transition matrixes for the
preventive programme. Two main conclusions are derived from
the sensitivity analysis carried out. Firstly, it seems that increas-
ing by 2% the discount rate for both cost and health outcomes
the cost-effectiveness of the preventive programme does not vary
so much. However, discounting costs and beneﬁts at 5% the pre-
ventive programme in both scenarios appears as cost-effective.
Secondly, it seems that increasing the cost of genetic testing up
to 100€ the cost-effectiveness of the preventive programme in
both scenarios remains practically stable. CONCLUSIONS: The
cost-effectiveness of an early genetic-screening and the preven-
tive strategy applied to all populations presenting the selected
ADAM33 remains at the limit of the cost-effectiveness. Never-
theless the model represents a valuable tool to prospectively
assess cost-effectiveness of preventive schemes based on genetic
screening.
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OBJECTIVES: Medication adherence rates (using the MPR)
were assessed among asthmatic patients who are under therapy
with an inhaled long-acting beta2-agonist + corticosteroids
(LABA+ICS) or a ﬁxed ﬂuticasone/salmeterol combination
(FSC).The differences between patients, who stick to their
therapy, compared to those, who switch between different
regimes or agents were analysed. METHODS: Claims data were
drawn from the IMS Database. Patients with asthma (°Y´18
years) who are under inhaled therapy according to the National
